Share on LinkedInShare on LinkedIn

ARTICLE · 20 JUNE 2013

Intellectual Property Weekly Abstracts Bulletin: Week Of June 10, 2013

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

In November, the Supreme Court issued its decision in the sildenafil case, and, as part of its order, found the patent to be invalid.

CanadaIntellectual Property

Edited by Chantal Saunders and Beverley Moore

IN THIS ISSUE

NOC Proceedings

Supreme Court Amends Order to Remove Declaration that Patent is Void
Teva Canada Limited v. Pfizer Canada Inc. et al., 33951
Drug: sildenafil

In November, the Supreme Court issued its decision in the sildenafil case, and, as part of its order, found the patent to be invalid. As this case was brought pursuant to the NOC Regulations, Pfizer brought a motion to amend that Order (reported here), and the Supreme Court has granted that motion. The order now states that Teva established its allegation that the patent is not valid. The Supreme Court also amended its order to give costs to Teva in the Courts below.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from